Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCG-TIME: Improving Response to Bacillus Calmette Guerin Immunotherapy in High-risk Non-muscle Invasive Bladder Cancer Via a Tumor Immune MicroEnvironment Based Biomarker.

NCT07064863 is registered in ClinicalTrials.gov with Queen's University as lead sponsor.

NCT NCT07064863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07064863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCG-TIME: Improving Response to Bacillus Calmette Guerin Immunotherapy in High-risk Non-muscle Invasive Bladder Cancer Via a Tumor Immune MicroEnvironment Based Biomarker.
Lead sponsor
Queen's University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
July 31, 2027
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer, nmibc, non-muscle invasive bladder urothelial carcinoma, urothelial carcinoma bladder